Rene Kahn: Clinical Trials

3 trials sponsored by Rene Kahn, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 42Completed 2

Follow Rene Kahn: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
European Long-acting Antipsychotics in Schizophrenia Trial-II
Schizophrenia
CompletedRene Kahn1592021-12-312026-11-10
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
Omega-3 fatty acids, Placebo - Ultra High Risk for Psychosis
Phase 4CompletedRene Kahn1462016-09-302026-11-17
Optimization of Treatment and Management of Schizophrenia in Europe
Amisulpride open label, 6-week amisulpride double blind treatment, 6-week olanzapine double blind treatment - Schizophrenia, Schizophreniform Disorder
Phase 4CompletedRene Kahn4792011-05-012018-05-15

Conditions studied

Psychotic Disorders (2)  ·  Schizophrenia (2)

Interventions

Fatty Acids, Omega-3 (1)  ·  Psychosocial Intervention (1)

Countries

Israel (3)  ·  Austria (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Norway (1)

Results publications

PMID 30115598, PMID 33536130, PMID 33838518, PMID 36988483, PMID 39450759

NIH funding

2015 (1)